Fraxa Research Foundation

The Brain Aneurysm Foundation, based in Hanover, MA, is a globally recognized leader in brain aneurysm awareness, education, support, advocacy, and research funding. Their mission is to promote early detection of brain aneurysms by providing knowledge and raising awareness of the signs, symptoms, and risk factors. They work closely with the medical communities to provide support networks for patients and families, as well as to further research that will improve patient outcomes and save lives. The foundation envisions a world without death or disability from brain aneurysms and aims to fill the gap in funding for research, as the federal government currently spends only $2.08 per year on brain aneurysm research for each person afflicted. Through their initiatives, they strive to make a significant impact in the field of brain aneurysm prevention, detection, and treatment, ultimately improving the lives of those affected by this condition.Generated from the website

Fraxa Research Foundation, based in Newburyport, MA, is dedicated to finding effective treatments and ultimately a cure for Fragile X syndrome, the most common inherited cause of autism and intellectual disabilities. The foundation funds groundbreaking research and clinical trials by partnering with top universities and biomedical companies worldwide, driven by a personal commitment from its staff and board, many of whom are parents of children affected by Fragile X. With a focus on advancing scientific understanding, Fraxa supports various research initiatives, including studies on the NMDA receptor and muscle function in children with Fragile X. The foundation has awarded numerous research grants and collaborates with pharmaceutical partners to bridge the gap between discovery and treatment, aiming to improve the lives of those impacted by Fragile X and related disorders. Generated from the website

The Progeria Research Foundation (PRF) is a dedicated non-profit organization focused on discovering treatments and potential cures for Progeria, an ultra-rare and fatal rapid-aging disease that affects children, leading to heart disease at an average age of 14.5 years. With ongoing research and FDA-approved treatment options like lonafarnib, PRF aims to improve the quality of life and extend the lifespan of those living with this condition. Committed to scientific advancement, PRF conducts numerous clinical trials and partners with international institutions to share knowledge and expertise in Progeria research. With a vision of a world where every child with Progeria is cured, the foundation actively engages with families, volunteers, and supporters to foster awareness, continuity, and innovation in their mission. Generated from the website